Proteon pulls in $15M in latest financing round
Long out of the financing picture, Waltham-based biopharmaceutical firm Proteon Therapeutics Inc. has drawn a new $15.2 million financing round, federal documents show.
The new funding round is in exchange for equity and options, according to the filing with the U.S. Securities and Exchange Commission. A total of 19 backers were involved in the round, but not listed by name. Previous investors in Proteon include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio IV NVS Strategic Fund LP, Vectis Healthcare & Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several angel investors.